Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

Pharmacopsychiatry

Volumn 40, Issue 6, 2007, Pages 257-263

  De Marinis, T ^b   Saleem, P T ^c   Glue, P ^d   Arnoldussen, W J ^e   Teijeiro, R ^f   Lex, A ^a   Latif, M A ^g   Medori, R ^a  

^a Janssen Cilag EMEA Belgium   (Belgium)

^b UO Salute Mentale ASL SA/2   (Italy)

^c Queen's Park Hospital   (United Kingdom)

^d Sygehus Fyn   (Denmark)

^e GGzE Foundation for Mental Health Care Eindhoven en de Kempen   (Netherlands)

^f CPRLab   (Netherlands)

^g SUSSEX COMMUNITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; IMPOTENCE; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 36849048918     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992140     Document Type: Article

References (25)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601
2. th edition. Washington, DC: American Psychiatric Association 1994
3. Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006; 39: 135-141
4. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizo Res 2005; 76: 247-265
5. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65:3: 354-360
6. Dossenbach MK, Beuzen J, Avon M, Belmaker RH, Elizur A, Mark M et al. The effectivenss of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000; 22: 1021-1034
7. Essock SM, Covell NH, Davis SM, Scott Stroup T, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163: 2090-2095
8. Godleski LS, Goldsmith J, Vieweg V, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry 2003; 64: 119-122
9. Han C, Lee BH, Kim YK, Lee HJ, Kim SH, Kim L et al. Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Prim Care Community Psychiatry 2005; 10: 119-124
10. Hugenholtz GK, Heerdink ER, Meijer WE, Stolker JJ, Egberts AG, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124
11. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-1132
12. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007; 68: 213-223
13. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004; 19: 219-225
14. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
15. Lin CH, Lin SC, Chen MC, Wang SY. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. J Chim Med Assoc 2006; 69: 264-269
16. Makela EH, Cutlip WD, Stevenson JM, Weimer JM, Abdallah ES et al. Brnaded versus generic clozaopine for treatment of schizophrenia. Ann Pharmacother 2003; 37: 350-353
17. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E, StoRMi Study Group. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121-130
18. Möller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005; 20: 379-385
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497
20. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatric Serv 2002; 53: 891-893
21. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
22. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006; 67: 1194-1203
23. Os J van, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004; 19: 229-232
24. Voruganti L, Cortese L, Oyewumi L, Cemovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135-145
25. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003; 64: 580-588